Universal Beteiligungs und Servicegesellschaft mbH Has $2.06 Million Holdings in Moderna, Inc. $MRNA

Universal Beteiligungs und Servicegesellschaft mbH trimmed its position in Moderna, Inc. (NASDAQ:MRNA) by 41.7% in the third quarter, HoldingsChannel.com reports. The firm owned 79,899 shares of the company’s stock after selling 57,182 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Moderna were worth $2,064,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Rothschild Investment LLC lifted its holdings in shares of Moderna by 94.1% during the 2nd quarter. Rothschild Investment LLC now owns 920 shares of the company’s stock worth $25,000 after acquiring an additional 446 shares during the period. Atlantic Union Bankshares Corp bought a new stake in Moderna in the second quarter valued at about $26,000. Whittier Trust Co. acquired a new position in Moderna in the second quarter worth about $28,000. MUFG Securities EMEA plc bought a new position in Moderna during the second quarter worth about $28,000. Finally, Cromwell Holdings LLC acquired a new stake in Moderna during the second quarter valued at approximately $33,000. 75.33% of the stock is owned by institutional investors.

Insider Buying and Selling at Moderna

In other news, Director Noubar Afeyan sold 23,853 shares of the stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $29.48, for a total transaction of $703,186.44. Following the sale, the director directly owned 3,924 shares of the company’s stock, valued at $115,679.52. This represents a 85.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 10.90% of the company’s stock.

Moderna Stock Performance

Shares of MRNA stock opened at $46.86 on Friday. Moderna, Inc. has a 52 week low of $22.28 and a 52 week high of $55.20. The stock has a market capitalization of $18.31 billion, a PE ratio of -5.81 and a beta of 1.17. The stock’s fifty day moving average is $33.55 and its 200-day moving average is $29.18.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.15) by $1.64. Moderna had a negative net margin of 139.61% and a negative return on equity of 29.81%. The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $893.29 million. During the same quarter in the prior year, the company earned $0.03 EPS. The firm’s quarterly revenue was down 45.4% on a year-over-year basis. As a group, analysts forecast that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Citigroup reissued a “neutral” rating on shares of Moderna in a report on Monday, January 19th. JPMorgan Chase & Co. dropped their price objective on Moderna from $26.00 to $25.00 and set an “underweight” rating for the company in a research note on Thursday, October 23rd. Jefferies Financial Group reissued a “hold” rating on shares of Moderna in a report on Monday, January 5th. Needham & Company LLC restated a “hold” rating on shares of Moderna in a research note on Monday, October 20th. Finally, Morgan Stanley dropped their target price on shares of Moderna from $30.00 to $28.00 and set an “equal weight” rating for the company in a research report on Friday, December 12th. Two equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and five have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Reduce” and an average target price of $28.77.

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.